However, patients in the KRAS group developed advanced polyps (log-rank 0.037) and, more specifically, advanced adenomas (log-rank 0.010), at higher rates than patients in the WT group (Fig 2A and 2B). The gene discussed is KRAS; the disease is adenoma.